focus -WSS

focus

author：leisure time 2025-09-30 17:29:54 - browse：48144

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Medicare proceeds with plan to claw back hospital funds

WSS

Lung cancer screening guidelines updated for cigarette smokers

After Sarepta trial failure, Duchenne families brace for more debate

Focused ultrasound for uterine fibroids: an uphill battle

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Coloradans with cystic fibrosis could lose access to Trikafta

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

knowledge

focus

explore

Cancer drug shortages should be causing more outrage

David Sabatini, ex

Moonlake's readout produced a cash windfall. Risks remain

Kidney transplant patients stopped immunosuppressants in trial

Medical leaders decry Supreme Court decision on affirmative action

Medicare proceeds with plan to claw back hospital funds

Tori Bowie and the unacceptable rates of Black maternal death

Life sciences investors close nearly $6 billion in new funds

ChatGPT in medicine: STAT answers readers' burning questions

Bill would allow buprenorphine prescription for addiction via telehealth

entertainment

Humans aren't the only ones with an imagination. Rats have it too

Insmed lung disease drug hits target in key Phase 3 trial

Childbirth

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

What will save rural psychiatry services? Higher Medicaid payments

Average age of first period drops to 11.9 years, study shows

focus

knowledge

focus

focus